Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Jeil Pharmaceutical Co., Ltd. Snapshot | 6 | 1 |
| Jeil Pharmaceutical Co., Ltd. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Jeil Pharmaceutical Co., Ltd. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Jeil Pharmaceutical Co., Ltd. Pipeline Review | 10 | 3 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Combination Treatment Modalities | 12 | 1 |
| Jeil Pharmaceutical Co., Ltd. Pipeline Products Glance | 13 | 4 |
| Jeil Pharmaceutical Co., Ltd. Late Stage Pipeline Products | 13 | 1 |
| Phase III Products/Combination Treatment Modalities | 13 | 1 |
| Jeil Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products | 14 | 1 |
| Phase I Products/Combination Treatment Modalities | 14 | 1 |
| Jeil Pharmaceutical Co., Ltd. Early Stage Pipeline Products | 15 | 1 |
| Preclinical Products/Combination Treatment Modalities | 15 | 1 |
| Discovery Products/Combination Treatment Modalities | 16 | 1 |
| Jeil Pharmaceutical Co., Ltd. Drug Profiles | 17 | 18 |
| (solifenacin succinate + tamsulosin hydrochloride) | 17 | 1 |
| Product Description | 17 | 1 |
| Mechanism of Action | 17 | 1 |
| R&D Progress | 17 | 1 |
| JLP-1401 | 18 | 1 |
| Product Description | 18 | 1 |
| Mechanism of Action | 18 | 1 |
| R&D Progress | 18 | 1 |
| metformin hydrochloride + rosuvastatin calcium | 19 | 1 |
| Product Description | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| R&D Progress | 19 | 1 |
| JJP-1305 | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 1 |
| JPI-289 | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 1 |
| JGK-263 | 22 | 1 |
| Product Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D Progress | 22 | 1 |
| JLP-1601 | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| JLP-1604 | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| JP-1366 | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| JP-2266 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| JPI-547 | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| Small Molecule for Degenerative Arthritis | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| Small Molecule for Hypertriglyceridaemia | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| Stem Cell Therapy for Parkinson's Disease and Age-Related Macular Degeneration | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 1 |
| JLP-1602 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| JLP-1603 | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| Small Molecule to Inhibit FLT3 for Acute Myeloid Leukemia | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| Small Molecules for Neuropathic Pain | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| Jeil Pharmaceutical Co., Ltd. Pipeline Analysis | 35 | 5 |
| Jeil Pharmaceutical Co., Ltd. Pipeline Products by Target | 35 | 2 |
| Jeil Pharmaceutical Co., Ltd. Pipeline Products by Route of Administration | 37 | 1 |
| Jeil Pharmaceutical Co., Ltd. Pipeline Products by Molecule Type | 38 | 1 |
| Jeil Pharmaceutical Co., Ltd. Pipeline Products by Mechanism of Action | 39 | 1 |
| Jeil Pharmaceutical Co., Ltd. Recent Pipeline Updates | 40 | 1 |
| Jeil Pharmaceutical Co., Ltd. Dormant Projects | 41 | 1 |
| Jeil Pharmaceutical Co., Ltd. Company Statement | 42 | 1 |
| Jeil Pharmaceutical Co., Ltd. Locations And Subsidiaries | 43 | 2 |
| Head Office | 43 | 1 |
| Other Locations &Subsidiaries | 43 | 2 |
| Appendix | 45 | 2 |
| Methodology | 45 | 1 |
| Coverage | 45 | 1 |
| Secondary Research | 45 | 1 |
| Primary Research | 45 | 1 |
| Expert Panel Validation | 45 | 1 |
| Contact Us | 45 | 1 |
| Disclaimer | 46 | 1 |